AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Vitiligo
If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.
If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.
The minimally invasive system uses real-time dual thermal monitoring and cannula-delivered energy to support skin firmness across the face and body.